Tuberculosis incidence after 36 months' isoniazid prophylaxis in HIV-infected adults in Botswana: A posttrial observational analysis

AIDS

Volumn 29, Issue 3, 2015, Pages 351-359

  Samandari, Taraz ^a   Agizew, Tefera B ^a   Nyirenda, Samba ^a   Tedla, Zegabriel ^a   Sibanda, Thabisa ^a   Mosimaneotsile, Barudi ^a   Motsamai, Oaitse I ^b   Shang, Nong ^a   Rose, Charles E ^c   Shepherd, James ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Department of HIV AIDS Prevention and Care   (Botswana)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

Antiretroviral therapy; HIV; Isoniazid; Preventive therapy; Tuberculin; Tuberculosis

Indexed keywords

EFAVIRENZ; ISONIAZID; LAMIVUDINE; NEVIRAPINE; PLACEBO; RIFAMPICIN; ZIDOVUDINE; TUBERCULOSTATIC AGENT;

ADULT; ANTIVIRAL THERAPY; ARTICLE; BOTSWANA; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DOSAGE SCHEDULE COMPARISON; DOUBLE BLIND PROCEDURE; DRUG DOSE REGIMEN; DRUG EFFICACY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANT TUBERCULOSIS; OBSERVATIONAL STUDY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TUBERCULIN TEST; TUBERCULOSIS; TUBERCULOSIS CONTROL; CLINICAL TRIAL; COMPLICATION; MULTICENTER STUDY; PRE-EXPOSURE PROPHYLAXIS; PROCEDURES;

ADULT; ANTITUBERCULAR AGENTS; BOTSWANA; DOUBLE-BLIND METHOD; FEMALE; HIV INFECTIONS; HUMANS; INCIDENCE; ISONIAZID; MALE; PLACEBOS; PRE-EXPOSURE PROPHYLAXIS; TUBERCULOSIS;

EID: 84927612872     PISSN: 02699370     EISSN: 14735571     Source Type: Journal    
DOI: 10.1097/QAD.0000000000000535     Document Type: Article

References (31)

1. Suthar AB, Lawn SD, del Amo J, Getahun H, Dye C, Sculier D, et al. Antiretroviral therapy for prevention of tuberculosis in adults with HIV: a systematic review and meta-analysis. PLoS Medicine 2012; 9:e1001270.
2. Ojikutu B, Makadzange AT, Gaolathe T. Scaling up ART treatment capacity: lessons learned from South Africa, Zimbabwe, and Botswana. Curr HIV/AIDS Rep 2008; 5:94-98.
3. Lawn SD, Myer L, Edwards D, Bekker L-G, Wood R. Short-term and long-term risk of tuberculosis associated with CD4 cell recovery during antiretroviral therapy in South Africa. AIDS 2009; 23:1717-1725.
4. Nicholas S, Sabapathy K, Ferreyra C, Varaine F, Pujades- Rodriguez N. Incidence of tuberculosis in HIV-infected patients before and after starting combined antiretroviral therapy in eight sub-Saharan African HIV Programs. JAIDS 2011; 57:311-318.
5. Van Rie A, Westreich D, Sanne I. Tuberculosis in patients receiving antiretroviral treatment: incidence, risk factors, and prevention strategies. JAIDS 2011; 56:349-355.
6. Hermans SM, Kiragga AN, Schaefer P, Kambugu A, Hoepleman AIM, Manabe Y. Incident tuberculosis during antiretroviral therapy contributes to suboptimal immune reconstitution in a large urban HIV clinic in sub-Saharan Africa. PLoS One 2010; 5:e10527.
7. Lawn SD, Harries AD, Williams BG, Chaisson RE, Losina E, De Cock KM, et al. Antiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it? Int J Tuberc Lung Dis 2011; 15:571-581.
8. Anon. Preventive therapy against tuberculosis in people living with HIV. Policy statement. Wkly Epidemiol Record 1999; 74:385-398.
9. Johnson JL, Okwera A, Hom DL, Mayanja H, Kityo CM, Nsubuga P, et al. Duration of efficacy of treatment of latent tuberculosis infection in HIV-infected adults. AIDS 2001; 15:2137-2147.
10. Quigley MA, Mwinga A, Hosp M, Lisse I, Fuchs D, Porter JD, et al. Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS 2001; 15:215-222.
11. Samandari T, Agizew TB, Nyirenda S, Sibanda T, Shang N, Mosimaneotsile B, et al. 6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebocontrolled trial. Lancet 2011; 377:1588-1598.
12. Golub JE, Saraceni V, Cavalcante SC, Pacheco AG, Moulton LH, King BS, et al. The impact of antiretroviral therapy and isoniazid preventive therapy on tuberculosis incidence in HIVinfected patients in Rio de Janeiro, Brazil. AIDS 2007; 21:1441-1448.
13. Golub JE, Pronyk P, Mohapi L, Thsabangu N, Moshabela M, Struthers H, et al. Isoniazid preventive therapy, HAART and tuberculosis risk in HIV-infected adults in South Africa: a prospective cohort. AIDS 2009; 23:631-636.
14. Mosimaneotsile B, Mathoma A, Chengeta B, Nyirenda S, Agizew TB, Tedla Z, et al. Isoniazid tuberculosis preventive therapy in HIV-infected adults accessing antiretroviral therapy: a Botswana experience, 2004-2006. JAIDS 2010; 54:71-77.
15. Martinson NA, Barnes GL, Moulton LH, Msandiwa R, Hausler H, Ram M, et al. New regimens to prevent tuberculosis in adults with HIV infection. New Engl J Med 2011; 365:11-20.
16. Golub JE, Saraceni V, Cavalcante SC, Cohn S, Pacheco A, Lau B, et al. Durability of isoniazid preventive therapy in HIV-positive patients in a medium burden TB setting. In: 20th Conference on Retroviruses and Opportunistic Infections: Abstract 190LB. Atlanta, 3-6 March 2013; Atlanta, Georgia.
17. Mekonen TT, Iyaloo J, Kalibbala M, Makai R, Hango JN, NkongoloOT, et al. Effect of primary isoniazid preventive therapy on tuberculosis incidence rate among HIV-infected adults enrolled in HIV care in northern Namibia: a retrospective cohort study. In: AIDS 2012 - XIX International AIDS Conference, 2012: Abstract WEPE066. 22-27 July 2012. Washington, D.C.
18. Churchyard GJ, Fielding KL, Lewis JJ, Coetzee L, Corbett EL, Godfrey-Faussett P, et al. A trial of mass isoniazid preventive therapy for tuberculosis control. New Engl J Med 2014; 370:301-310.
19. Gordin F, Chaisson RE, Matts JP, Miller C, de Lourdes Garcia M, Hafner R, et al. Rifampin and pyrazinamide vs isoniazid for prevention of tuberculosis in HIV-infected persons: an international randomized trial. JAMA 2000; 283:1445-1450.
20. Kabali C, von Reyn CF, Brooks DR, Waddell R, Mtei L, Bakari M, et al. Completion of isoniazid preventive therapy and survival in HIV-infected, TST-positive adults in Tanzania. Int J Tuberc Lung Dis 2011; 15:1515-1521.
21. Charalambous S, Grant AD, Innes C, Hoffmann CJ, Dowdeswell R, Pienaar J, et al. Association of isoniazid preventive therapy with lower early mortality in individuals on antiretroviral therapy in a workplace programme. AIDS 2010; 24 (Suppl 5): S5-S13.
22. Durovni B, Saraceni V, Moulton LH, Pacheco AG, Cavalcante SC, King BS, et al. Effect of improved tuberculosis screening and isoniazid preventive therapy on incidence of tuberculosis and death in patients with HIV in clinics in Rio de Janeiro, Brazil: a stepped wedge, cluster-randomised trial. Lancet Infect Dis 2013; 13:852-858.
23. Akolo C, Adetifa I, Shepperd S, Volmink J. Treatment of latent tuberculosis infection in HIV infected persons. Cochrane Database Syst Rev 2010; 1:CD000171.
24. Rangaka MX, Wilkinson RJ, Boulle A, Glynn JR, Fielding K, van Cutsem G, et al. Isoniazid plus antiretroviral therapy to prevent tuberculosis: a randomized double-blind, placebo-controlled trial. Lancet 2014; 384:682-690.
25. Grant AD, Fielding KL, Charalambous S, Chaisson RE, Churchyard GJ. Why have trials of isoniazid preventive therapy among people with HIV infection not demonstrated an effect on mortality? Did close examination of the trees obscure our view of the wood?. AIDS 2010; 24 (Suppl 5): S15-S18.
26. Gupta A, Wood R, Kaplan R, Bekker L-G, Lawn SD. Tuberculosis incidence rates during 8 years of follow-up of an antiretroviral treatment cohort in South Africa: comparison with rates in the community. PLoS One 2012; 7:e34156.
27. Pettit AC, Jenkins CA, Stinnette SE, Rebeiro PF, Blackwell RB, Raffanti SP, et al. Tuberculosis risk before and after highly active antiretroviral therapy initiation: does HAART Increase the short-term TB risk in a low incidence TB setting? J Acquir Immune Defic Syndr 2011; 57:305-310.
28. Grinsztejn B, Hosseinipour MC, Ribaudo HJ, Swindells S, Eron J, Chen YQ, et al. Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. New Engl J Med 2014; 14:281-290.
29. Lin AWC, Chan KCW, Chan WK, Wong KH. Tuberculin sensitivity testing and treatment of latent tuberculosis remains effective for tuberculosis control in human immunodeficiency virus-infected patients in Hong Kong. Hong Kong Med J 2013; 19:386-392.
30. Martínez-Pino I, Sambeat MA, Lacalle-Remigio JR, Domingo Pand the VACH Cohort Study Group. Incidence of tuberculosis in HIV-infected patients in Spain: the impact of treatment for LTBI. Int J Tuberc Lung Dis 2015; 17:1545-1551.
31. Khawcharoenporn T, Apisarnthanarak A, Manosuthi W, Sungkanuparph S, Mundy LM. Isoniazid preventive therapy and 4-year incidence of pulmonary tuberculosis among HIV-infected Thai patients. Int J Tuberc Lung Dis 2012; 16:336-341.